Biotinylated Recombinant Human Mesothelin/MSLN Protein

Artikelnummer: ABB-RP02449B
Artikelname: Biotinylated Recombinant Human Mesothelin/MSLN Protein
Artikelnummer: ABB-RP02449B
Hersteller Artikelnummer: RP02449B
Alternativnummer: ABB-RP02449B-100UG
Hersteller: ABclonal
Wirt: Human
Kategorie: Proteine/Peptide
Spezies Reaktivität: Human
Immunogen: Glu296-Gly580
Alternative Synonym: MPF, SMRP,MSLN,SMRP
Mesothelin, also known as MSLN, is a protein that in humans is encoded by the MSLN gene.Cloning studies showed that the mesothelin gene encodes a precursor protein that is processed to yield mesothelin which is attached to the cell membrane by a glycophosphatidylinositol linkage and a 31-kDa shed fragment named megakaryocyte-potentiating factor (MPF). Although it has been proposed that mesothelin may be involved in cell adhesion, its biological function is not known.A knockout mouse line that lacks mesothelin reproduces and develops normally.
Konzentration: < 1 EU/µg of the protein by LAL method.
Molekulargewicht: 61.1 kDa
NCBI: 10232
UniProt: Q13421
Reinheit: 95 % as determined by Tris-Bis PAGE, 95 % as determined by HPLC.
Formulierung: Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Sequenz: EVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGL
Target-Kategorie: Mesothelin/MSLN
Application Verdünnung: Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Anwendungsbeschreibung: Cross-Reactivity: Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage,it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA,5% HSA,10% FBS or 5% Trehalose),and aliquot the reconstituted protein solution to minimize free-thaw cycles. ResearchArea: CAR-T Cell Therapy Targets,Biosimilar Drug Targets